AbbVie Inc. (NYSE:ABBV) Shares Bought by Helen Stephens Group LLC

Helen Stephens Group LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 4.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,369 shares of the company’s stock after purchasing an additional 61 shares during the quarter. Helen Stephens Group LLC’s holdings in AbbVie were worth $243,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Sax Wealth Advisors LLC grew its stake in AbbVie by 14.0% in the 4th quarter. Sax Wealth Advisors LLC now owns 6,594 shares of the company’s stock valued at $1,172,000 after acquiring an additional 810 shares during the period. Somerset Trust Co boosted its position in AbbVie by 21.7% during the fourth quarter. Somerset Trust Co now owns 3,281 shares of the company’s stock worth $583,000 after acquiring an additional 584 shares during the last quarter. Merit Financial Group LLC boosted its holdings in shares of AbbVie by 2.9% during the 4th quarter. Merit Financial Group LLC now owns 49,226 shares of the company’s stock worth $8,747,000 after purchasing an additional 1,375 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services boosted its stake in AbbVie by 1.2% during the fourth quarter. First National Bank of Mount Dora Trust Investment Services now owns 56,949 shares of the company’s stock worth $10,120,000 after buying an additional 701 shares during the last quarter. Finally, Chemistry Wealth Management LLC grew its holdings in AbbVie by 3.3% in the 4th quarter. Chemistry Wealth Management LLC now owns 8,916 shares of the company’s stock valued at $1,584,000 after buying an additional 282 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ABBV. Piper Sandler raised their price objective on shares of AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. JPMorgan Chase & Co. lowered their price objective on AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. UBS Group upped their price target on AbbVie from $195.00 to $200.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Daiwa America cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 5th. Finally, Sanford C. Bernstein assumed coverage on shares of AbbVie in a report on Thursday, October 17th. They issued a “market perform” rating and a $203.00 target price for the company. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $205.50.

AbbVie Stock Performance

Shares of ABBV opened at $171.49 on Friday. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The stock has a market capitalization of $303.05 billion, a P/E ratio of 59.55, a P/E/G ratio of 1.73 and a beta of 0.58. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The company’s fifty day moving average is $175.78 and its two-hundred day moving average is $184.47.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.28 billion. During the same period in the prior year, the business posted $2.95 EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, sell-side analysts predict that AbbVie Inc. will post 10.06 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a dividend of $1.64 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, January 15th. AbbVie’s dividend payout ratio (DPR) is 215.28%.

Insiders Place Their Bets

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.25% of the stock is currently owned by company insiders.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.